Search

Search Constraints

You searched for: Author/Creator He, Shui

Search Results

2. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Issue 4 (30th October 2013)

3. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Issue 4 (30th October 2013)

4. Bionic microstructure on titanium alloy blade with belt grinding and its drag reduction performance. (December 2021)

5. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Issue 6 (June 2021)

7. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Issue 6 (June 2021)